Abstract | BACKGROUND: METHODS: We performed a meta-analysis of individual patient data from four randomized trials including 583 patients comparing sirolimus eluting with bare metal stents (median follow-up of 4.2 years). These were the only specific trials reporting on drug-eluting stents in diabetic patients. The primary endpoint was the incidence of major cardiac events. The secondary endpoints were all-cause mortality and myocardial infarction as a safety endpoint and target lesion re-intervention as an efficacy endpoint. Stent thrombosis was also evaluated. RESULTS: There was a significant reduction in the overall hazard of major cardiac events (hazard ratio [HR] 0.48, 95% confidence interval [CI] 0.36-0.63, P < 0.001) with sirolimus-eluting stents. This was mostly due to a significant reduction in the overall hazard of repeat revascularization (HR 0.27, 95% CI 0.18-0.41, P < 0.001) in favor of sirolimus-eluting stents. However, the overall hazard of death (HR 0.91, 95% CI 0.59-1.41, P = 0.68) as well as death or myocardial infarction (HR 0.77, 95% CI 0.54-1.09, P = 0.14) were not significantly different between the groups. No significant differences were observed regarding stent thrombosis (HR 0.50, 95% CI 0.15-1.69, P = 0.26). CONCLUSIONS:
|
Authors | Antoinette de Waha, Alban Dibra, Sebastian Kufner, Dietrich Baumgart, Manel Sabate, Aleardo Maresta, Albert Schömig, Adnan Kastrati |
Journal | Clinical research in cardiology : official journal of the German Cardiac Society
(Clin Res Cardiol)
Vol. 100
Issue 7
Pg. 561-70
(Jul 2011)
ISSN: 1861-0692 [Electronic] Germany |
PMID | 21221607
(Publication Type: Comparative Study, Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Aged
- Coronary Artery Disease
(complications, mortality, therapy)
- Diabetes Complications
- Drug-Eluting Stents
(adverse effects)
- Follow-Up Studies
- Humans
- Middle Aged
- Randomized Controlled Trials as Topic
- Sirolimus
- Stents
(adverse effects)
- Treatment Outcome
|